News Lilly puts up to $2.75bn into Insilico alliance Insilico has once again added to its roster of big pharma partners, signing a deal with Eli Lilly that includes a $115m upfront payment.
News AI in drug discovery and development: news watch Recent developments in the biopharma AI world include a big financing for Verily, and updates from Zealand, Latent Labs, Insilico, and BMS/insitro.
News AI in drug development news round-up Recent developments in biopharma AI include an alliance between Thermo and Datavant, plus news from Insilico, Evinova, BPGbio, Evogene, and AMPLY.
News Insilico adds Servier to partnership roster with $888m deal Insilico has added to its partnerships list with an $888m cancer-focused alliance with Servier, just days after completing its long-awaited IPO.
News Insilico ends 2025 with $293m Hong Kong IPO One of the pioneers in AI-powered drug discovery, Insilico Medicine, has completed an oversubscribed IPO in Hong Kong, raising around $293m.
News MSD's $349m alliance with Variational, and other AI news MSD signs $345m alliance with Variational AI, plus updates on AI in drug discovery projects from Bio Protocol, Dalton Tx, Virginia Tech, and Insilico.
Patients LSX2026: On promise and patience, with Hans Schambye At LSX World Congress 2026 in Lisbon, Portugal, web editor Nicole Raleigh spoke with Hans Schambye, CEO of BOOST Pharma.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
